![]() |
市場調查報告書
商品編碼
1492506
女性不孕症診斷和治療市場:按產品、治療、診斷、不孕原因和最終用戶 - 全球預測 2024-2030Female Infertility Diagnosis & Treatment Market by Product (Accessories, Equipment, Media), Treatment (Assisted Reproductive Technology, Medication, Surgery), Diagnosis, Cause of Infertility, End User - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年女性不孕症診斷與治療市場規模為18.1億美元,2024年達19.6億美元,2030年達31.4億美元,複合年成長率為8.11%。
女性不孕症的診斷和治療是全面性的,旨在解決與女性不孕症相關的原因和治療方法。診斷和治療解決方案是一體化的,從荷爾蒙評估和影像檢查到先進的輔助生殖技術 (ART),包括體外受精 (IVF) 和手術干預。由於生活方式因素的變化,例如初為人母的老化、肥胖率上升以及包括多囊性卵巢症候群在內的相關健康狀況,女性不孕症發生率不斷上升,這增加了對女性不孕症診斷和治療的需求。此外,人們對不孕症問題的認知不斷提高,社會對接受治療的接受程度不斷提高,也支持了市場的成長。然而,由於ART和其他不孕症治療費用昂貴,女性不孕症診斷和治療的推廣受到限制。此外,人工智慧和機器學習在女性不孕症診斷和治療中的整合將提高診斷準確性、預測治療結果、提高整體治療效果並支持未來的成長。
主要市場統計 | |
---|---|
基準年[2023] | 18.1億美元 |
預測年份 [2024] | 19.6億美元 |
預測年份 [2030] | 31.4億美元 |
複合年成長率(%) | 8.11% |
區域洞察
由於較高的消費者意識、強大的醫療基礎設施和有利的政府政策,美洲對不孕症治療的需求強烈。尤其是美國和加拿大,處於個人化醫療的前沿,正在大力投資相關研究,擴大創新治療方法選擇。由於人們認知的提高和醫療干預措施的可用性的增加,南美洲女性不孕症診斷和治療市場正在經歷顯著的市場開拓。歐洲擁有強大的醫療保健系統和法規,可確保較高的患者照護和資料安全標準,並為不孕症治療創造一個值得信賴的環境。在中東和非洲,不斷擴大的醫療保健投資以及擴大不孕症治療相關設施和服務是市場成長的驅動力。由於具有成本效益的治療和不斷提高的醫療水平,亞太地區已成為醫療旅遊中心。在中國和印度,消費者的需求是由成本、文化可接受性和技術可用性所驅動的。由於較高的收入水平和較高的意識,這些國家的都市區更有可能採用先進的醫療保健。
FPNV定位矩陣
FPNV定位矩陣對於評估供應商在女性不孕症診斷和治療市場的定位至關重要。此矩陣提供了對供應商的全面評估,並檢驗了與商務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對女性不孕症診斷和治療市場中供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻,您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他重要指標。此外,該分析還提供了對該行業競爭性質的寶貴見解,包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並製定有效的策略,以在市場競爭中保持領先地位。
策略分析與建議
策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對目前在女性不孕症診斷和治療市場中的地位進行全面評估,使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析,以確定核心優勢和需要改進的領域。
[195 Pages Report] The Female Infertility Diagnosis & Treatment Market size was estimated at USD 1.81 billion in 2023 and expected to reach USD 1.96 billion in 2024, at a CAGR 8.11% to reach USD 3.14 billion by 2030.
The female infertility diagnosis & treatment are comprehensively structured to address the causes and treatments associated with infertility in women. It integrates diagnostic and therapeutic solutions, from hormonal assessments and imaging tests to advanced assisted reproductive technologies (ART), including in vitro fertilization (IVF) and surgical interventions. Increased infertility rates in females due to changes in lifestyle factors, such as higher age of first-time mothers, rising obesity rates, and associated health conditions, including PCOS, are raising the need for female infertility diagnosis & treatments. Moreover, growing awareness about fertility issues and greater social acceptance for seeking treatment support market growth. However, the high cost of ART and other infertility treatment limits patients to adopt female infertility diagnoses and treatments. Furthermore, the integration of AI and machine learning in female infertility diagnosis & treatment improves diagnostic accuracy and predict treatment outcomes, enhancing overall treatment efficacy and supporting future growth.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 1.81 billion |
Estimated Year [2024] | USD 1.96 billion |
Forecast Year [2030] | USD 3.14 billion |
CAGR (%) | 8.11% |
Regional Insights
In the Americas, high consumer awareness, robust healthcare infrastructure, and favorable government policies drive a strong need for infertility treatments. The countries, notably the United States and Canada, are at the forefront of adopting personalized medicine approaches and investing heavily in related research, thus pushing the envelope in innovative treatment options. The South American market for female infertility diagnosis & treatment is undergoing notable development, driven by enhanced awareness and the increasing availability of medical interventions. Europe, with its robust healthcare systems and regulations, ensures high patient care and data safety standards, fostering a reliable environment for infertility treatments. In the Middle East and Africa, growing healthcare investments and enhancing facilities and services related to infertility treatments drive market growth. The Asia Pacific region is a hub for medical tourism due to cost-effective treatments and rising healthcare standards. In China and India, consumer needs are driven by cost, cultural acceptance, and technology availability. Urban areas in these countries show a higher propensity for adopting advanced medical treatments due to higher income levels and better awareness.
Market Insights
The market dynamics represent an ever-changing landscape of the Female Infertility Diagnosis & Treatment Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Female Infertility Diagnosis & Treatment Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Female Infertility Diagnosis & Treatment Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Lupin Introduces New Generic Infertility Treatment in the U.S. Market
Lupin Limited announced the U.S. launch of its Ganirelix Acetate Injection, 250 mcg/0.5 mL, in a Single-Dose Prefilled Syringe, following the United States Food and Drug Administration (FDA) approval. This product is the generic version of Organon USA LLC's Ganirelix Acetate Injection and is designed to prevent premature luteinizing hormone rise in women undergoing controlled ovarian hyperstimulation. [Published On: 2024-02-16]
Arva Health's Innovative At-Home Fertility Test for Indian Women
Arva Health introduced an at-home fertility test developed with leading fertility experts. This test uniquely measures up to 12 hormonal levels pertinent to fertility, allowing women to conveniently assess their reproductive health from home. This is both cost-effective and non-intrusive compared to traditional clinic visits. Arva Health illuminates aspects of the biological clock and potential reproductive issues and equips women with the knowledge to manage their fertility journey proactively at their convenience and discretion. [Published On: 2023-12-13]
Trajan Scientific and German Startup Fertilly Introduce Microsampling-based Fertility Test Kits in Europe
Trajan Scientific and Medical partnered with Fertility to launch Europe's first-at-home fertility test kits. These kits incorporate advanced dried blood microsampling technology. Fertilly's move, supported by Trajan Scientific's innovative technologies, represents a crucial step towards democratizing fertility assessments and enabling more informed decisions regarding family planning. [Published On: 2023-08-15]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Female Infertility Diagnosis & Treatment Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Female Infertility Diagnosis & Treatment Market, highlighting leading vendors and their innovative profiles. These include Bayer AG, Cook Group Incorporated, CooperSurgical Inc., Ferring B.V., FUJIFILM Irvine Scientific, Inc. by FUJIFILM Holdings Corporation, Genea Pty Limited, GlaxoSmithKline PLC, Halotech DNA S.L., Intas Pharmaceuticals Ltd., Lupin Limited, Merck & Co., Inc., Novartis AG, Sanofi SA, SCSA Diagnostics, Inc., Theramex by Kanga Health Ltd, and Vitrolife Sweden AB.
Market Segmentation & Coverage